Optimus Receives Tentative Approval from U.S. FDA for Brexpiprazole Tablets

Hyderabad (Telangana) [India], October 09: Optimus Pharma Private Limited today announced that it has received tentative approval from the United States Food and Drug Administration (FDA) for the generic equivalent of Rexulti® Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg, of Otsuka Pharmaceutical Co., Ltd. Optimus Pharma’s approval for its Abbreviated New Drug Application (ANDA) BREXPIPRAZOLE Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg, was received on October 8th, 2021. BREXPIPRAZOLE will be manufactured at Optimus Pharma’s Pashmylaram USFDA accredited facility in India.

BREXPIPRAZOLE Tablets (RLD: Rexulti® Tablets) had estimated annual sales of USD 1258 million in the U.S. (IQVIA MAT July 2021).

BREXPIPRAZOLE has a favourable antipsychotic profile in terms of improvement of cognitive performance and sleep patterns, as well as effects on affective states and potential to treat core symptoms in schizophrenia and major depressive disorder, including cognitive deficits with a low risk of adverse effects (extrapyramidal symptoms, metabolic complications, weight gain, akathisia potential) that are commonly encountered with other typical and second-generation antipsychotic drugs. From the studies done so far, it can be concluded that BREXPIPRAZOLE can be effective monotherapy for schizophrenia and as an adjunct to other antidepressant medications in major depressive disorder.

About Optimus Pharma

Optimus was established in the year 2004 as a custom synthesis laboratory by a team of techno-commercial experts. It is one of the fastest-growing Manufacturer in Active Pharmaceutical Ingredients (APIs) and Finished dosages. Over the last decade, we have been certified and audited by reputed Global Regulatory Agencies like USFDA, WHO, COFEPRIS, EMA, KFDA and AFM from PMDA Japan. Optimus Pharma is a vertically integrated pharmaceutical company engaged in the manufacturing of Solid Oral and semisolid formulations. We have successfully integrated our API and Formulation R&D teams, with the IP and Regulatory Affairs team in order to ensure a dynamic product portfolio. We help our customers serve global markets with technology based, innovative, cost effective & consumer friendly products of the highest quality.

Related Posts

Illuminating Spaces with Hafele’s Lighting, Transforming Every Corner

New Delhi [India], March 18: Hafele’s Loox Range has been meeting the demands for lighting in furniture as well as the growing needs for networking and digitalization since the last…

Hafele Introduces a New Perspective to Home Security

New Delhi [India], March 18: Hafele introduces a new perspective to home security with its integrated range of Digital Home Security Solutions. With this range we bring to you the…

You Missed

Hyderabad Angels Fund (HAF) Launches SEBI Category 1 Fund to Boost Early-Stage Startup Investments

  • March 18, 2025
Hyderabad Angels Fund (HAF) Launches SEBI Category 1 Fund to Boost Early-Stage Startup Investments

India 2047: Paving the Path to a Climate-Resilient Future: Harvard Joins MoEFCC for Key Conference

  • March 18, 2025
India 2047: Paving the Path to a Climate-Resilient Future: Harvard Joins MoEFCC for Key Conference

Marwah Studios Celebrates 34 Years of Innovation and Leadership in Media

  • March 18, 2025
Marwah Studios Celebrates 34 Years of Innovation and Leadership in Media

Indulge at the 25th IIFA Awards 2025 with Shakkr Gifting and Saltt Catering for Luxurious Gala Dining!

  • March 13, 2025
Indulge at the 25th IIFA Awards 2025 with Shakkr Gifting and Saltt Catering for Luxurious Gala Dining!

ET Now Business Conclave Honors Dr. Dinesh Shahra with Best Author Award in Sanatan Literacy

  • March 13, 2025
ET Now Business Conclave Honors Dr. Dinesh Shahra with Best Author Award in Sanatan Literacy

Lubi Industries Partners With Sunrisers Hyderabad For Upcoming T20 Tournament 2025

  • March 13, 2025
Lubi Industries Partners With Sunrisers Hyderabad For Upcoming T20 Tournament 2025